[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.240.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Grabowski  GA, Zimran  A, Ida  H.  Gaucher disease types 1 and 3.  Am J Hematol. 2015;90(suppl 1):S12-S18. PubMedGoogle ScholarCrossref
2.
Sidransky  E, Nalls  MA, Aasly  JO,  et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease.  N Engl J Med. 2009;361(17):1651-1661. PubMedGoogle ScholarCrossref
3.
Rana  HQ, Balwani  M, Bier  L, Alcalay  RN.  Age-specific Parkinson disease risk in GBA mutation carriers.  Genet Med. 2013;15(2):146-149. PubMedGoogle ScholarCrossref
4.
Anheim  M, Elbaz  A, Lesage  S,  et al; French Parkinson Disease Genetic Group.  Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers.  Neurology. 2012;78(6):417-420. PubMedGoogle ScholarCrossref
5.
Zhang  Y, Shu  L, Sun  Q,  et al.  Integrated genetic analysis of racial differences of common GBA variants in Parkinson’s disease: a meta-analysis.  Front Mol Neurosci. 2018;11:43. PubMedGoogle ScholarCrossref
6.
Yang  SY, Beavan  M, Chau  KY, Taanman  JW, Schapira  AHV.  A human neural crest stem cell–derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers.  Stem Cell Reports. 2017;8(3):728-742. PubMedGoogle ScholarCrossref
7.
Migdalska-Richards  A, Daly  L, Bezard  E, Schapira  AH.  Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.  Ann Neurol. 2016;80(5):766-775. PubMedGoogle ScholarCrossref
8.
Migdalska-Richards  A, Ko  WKD, Li  Q, Bezard  E, Schapira  AHV.  Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.  Synapse. 2017;71(7):e21967. PubMedGoogle Scholar
9.
Magalhaes  J, Gegg  ME, Migdalska-Richards  A, Schapira  AH.  Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons.  Sci Rep. 2018;8(1):1385. PubMedGoogle ScholarCrossref
10.
Mazzulli  JR, Zunke  F, Tsunemi  T,  et al.  Activation of β-glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson’s patient midbrain neurons.  J Neurosci. 2016;36(29):7693-7706. PubMedGoogle ScholarCrossref
11.
McNeill  A, Magalhaes  J, Shen  C,  et al.  Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.  Brain. 2014;137(pt 5):1481-1495. PubMedGoogle ScholarCrossref
12.
Gegg  ME, Burke  D, Heales  SJ,  et al.  Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains.  Ann Neurol. 2012;72(3):455-463. PubMedGoogle ScholarCrossref
13.
Murphy  KE, Gysbers  AM, Abbott  SK,  et al.  Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease.  Brain. 2014;137(pt 3):834-848. PubMedGoogle ScholarCrossref
14.
Parnetti  L, Chiasserini  D, Persichetti  E,  et al.  Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease.  Mov Disord. 2014;29(8):1019-1027. PubMedGoogle ScholarCrossref
15.
Sardi  SP, Clarke  J, Viel  C,  et al.  Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.  Proc Natl Acad Sci U S A. 2013;110(9):3537-3542. PubMedGoogle ScholarCrossref
16.
Mullin  S, Hughes  D, Mehta  A, Schapira  AHV.  Neurological effects of glucocerebrosidase gene mutations.  Eur J Neurol. 2019;26(3):388-e29. PubMedGoogle ScholarCrossref
17.
Narita  A, Shirai  K, Itamura  S,  et al.  Ambroxol chaperone therapy for neuronopathic Gaucher disease.  Ann Clin Transl Neurol. 2016;3(3):200-215. PubMedGoogle ScholarCrossref
18.
Maegawa  GH, Tropak  MB, Buttner  JD,  et al.  Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.  J Biol Chem. 2009;284(35):23502-23516. PubMedGoogle ScholarCrossref
19.
Bendikov-Bar  I, Maor  G, Filocamo  M, Horowitz  M.  Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.  Blood Cells Mol Dis. 2013;50(2):141-145. PubMedGoogle ScholarCrossref
20.
Luan  Z, Li  L, Higaki  K, Nanba  E, Suzuki  Y, Ohno  K.  The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice.  Brain Dev. 2013;35(4):317-322. PubMedGoogle ScholarCrossref
21.
Xilouri  M, Brekk  OR, Stefanis  L.  α-Synuclein and protein degradation systems: a reciprocal relationship.  Mol Neurobiol. 2013;47(2):537-551. PubMedGoogle ScholarCrossref
22.
Yap  TL, Gruschus  JM, Velayati  A,  et al.  Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.  J Biol Chem. 2011;286(32):28080-28088. PubMedGoogle ScholarCrossref
23.
Fois  G, Hobi  N, Felder  E,  et al.  A new role for an old drug.  Cell Calcium. 2015;58(6):628-637. PubMedGoogle ScholarCrossref
24.
Maor  G, Rencus-Lazar  S, Filocamo  M, Steller  H, Segal  D, Horowitz  M.  Unfolded protein response in Gaucher disease: from human to drosophila.  Orphanet J Rare Dis. 2013;8:140. PubMedGoogle ScholarCrossref
25.
Babajani  G, Tropak  MB, Mahuran  DJ, Kermode  AR.  Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells.  Mol Genet Metab. 2012;106(3):323-329. PubMedGoogle ScholarCrossref
26.
World Medical Association.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.  JAMA. 2013;310(20):2191-2194. PubMedGoogle ScholarCrossref
27.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1). https://apps.who.int/medicinedocs/documents/s22154en/s22154en.pdf. Published June 10, 1996. Accessed December 5, 2019.
28.
Hughes  AJ, Daniel  SE, Kilford  L, Lees  AJ.  Accuracy of clinical diagnosis of idiopathic Parkinson’s disease.  J Neurol Neurosurg Psychiatry. 1992;55(3):181-184. PubMedGoogle ScholarCrossref
29.
Rocha  EM, Smith  GA, Park  E,  et al.  Sustained systemic glucocerebrosidase inhibition induces brain α-synuclein aggregation, microglia and complement C1q activation in mice.  Antioxid Redox Signal. 2015;23(6):550-564. PubMedGoogle ScholarCrossref
30.
Schirinzi  T, Sancesario  GM, Di Lazzaro  G,  et al.  CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients.  Parkinsonism Relat Disord. 2019;61:203-206. PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 7,061
    Citations 0
    Original Investigation
    January 13, 2020

    Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial

    Author Affiliations
    • 1Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
    • 2Institute of Translational and Stratified Medicine, University of Plymouth School of Medicine, Plymouth, United Kingdom
    • 3NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    • 4Translational Mass Spectrometry Research Group, University College London Institute of Child Health, London, United Kingdom
    • 5Department of Medical Statistics, University of Plymouth School of Medicine, Plymouth, United Kingdom
    • 6Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, United Kingdom
    • 7Department of Neurodegenerative Disease, University College London Institute of Neurology, London, United Kingdom
    • 8UK Dementia Research Institute at University College London, London, United Kingdom
    • 9Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden
    • 10Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    JAMA Neurol. Published online January 13, 2020. doi:10.1001/jamaneurol.2019.4611
    Key Points

    Question  Does ambroxol cross the blood-brain barrier, and what are the biochemical changes associated with ambroxol therapy in patients with Parkinson disease with and without glucocerebrosidase gene mutations?

    Findings  In this open-label clinical trial of 17 patients with Parkinson disease, ambroxol crossed the blood-brain barrier and bound to the β-glucocerebrosidase enzyme, and it increased β-glucocerebrosidase enzyme protein levels and cerebrospinal fluid α-synuclein levels in patients both with and without glucocerebrosidase gene mutations.

    Meaning  Ambroxol therapy has potential for study as a neuroprotective compound for the treatment of patients with Parkinson disease both with and without glucocerebrosidase gene mutations.

    Abstract

    Importance  Mutations of the glucocerebrosidase gene, GBA1 (OMIM 606463), are the most important risk factor for Parkinson disease (PD). In vitro and in vivo studies have reported that ambroxol increases β-glucocerebrosidase (GCase) enzyme activity and reduces α-synuclein levels. These observations support a potential role for ambroxol therapy in modifying a relevant pathogenetic pathway in PD.

    Objective  To assess safety, tolerability, cerebrospinal fluid (CSF) penetration, and target engagement of ambroxol therapy with GCase in patients with PD with and without GBA1 mutations.

    Interventions  An escalating dose of oral ambroxol to 1.26 g per day.

    Design, Setting, and Participants  This single-center open-label noncontrolled clinical trial was conducted between January 11, 2017, and April 25, 2018, at the Leonard Wolfson Experimental Neuroscience Centre, a dedicated clinical research facility and part of the University College London Queen Square Institute of Neurology in London, United Kingdom. Participants were recruited from established databases at the Royal Free London Hospital and National Hospital for Neurology and Neurosurgery in London. Twenty-four patients with moderate PD were evaluated for eligibility, and 23 entered the study. Of those, 18 patients completed the study; 1 patient was excluded (failed lumbar puncture), and 4 patients withdrew (predominantly lumbar puncture–related complications). All data analyses were performed from November 1 to December 14, 2018.

    Main Outcomes and Measures  Primary outcomes at 186 days were the detection of ambroxol in the CSF and a change in CSF GCase activity.

    Results  Of the 18 participants (15 men [83.3%]; mean [SD] age, 60.2 [9.7] years) who completed the study, 17 (8 with GBA1 mutations and 9 without GBA1 mutations) were included in the primary analysis. Between days 0 and 186, a 156-ng/mL increase in the level of ambroxol in CSF (lower 95% confidence limit, 129 ng/mL; P < .001) was observed. The CSF GCase activity decreased by 19% (0.059 nmol/mL per hour; 95% CI, –0.115 to –0.002; P = .04). The ambroxol therapy was well tolerated, with no serious adverse events. An increase of 50 pg/mL (13%) in the CSF α-synuclein concentration (95% CI, 14-87; P = .01) and an increase of 88 ng/mol (35%) in the CSF GCase protein levels (95% CI, 40-137; P = .002) were observed. Mean (SD) scores on part 3 of the Movement Disorders Society Unified Parkinson Disease Rating Scale decreased (ie, improved) by 6.8 (7.1) points (95% CI, –10.4 to –3.1; P = .001). These changes were observed in patients with and without GBA1 mutations.

    Conclusions and Relevance  The study results suggest that ambroxol therapy was safe and well tolerated; CSF penetration and target engagement of ambroxol were achieved, and CSF α-synuclein levels were increased. Placebo-controlled clinical trials are needed to examine whether ambroxol therapy is associated with changes in the natural progression of PD.

    Trial Registration  ClinicalTrials.gov identifier: NCT02941822; EudraCT identifier: 2015-002571-24

    ×